Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Not Yet Opened 02-04 16:00:00 EST

14.62

-0.91

-5.86%

盘后15.12

+0.50+3.42%

19:15 EST

High15.75	Low14.54	Vol823.95K
Open15.53	D1 Closing15.53	Amplitude7.79%
Mkt Cap457.46M	Tradable Cap229.42M	Total Shares31.29M
T/O12.28M	T/O Rate5.25%	Tradable Shares15.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":14.62,"timestamp":1770238800000,"preClose":15.53,"halted":0,"volume":823953,"hourTrading":{"tag":"盘后","latestPrice":15.12,"preClose":14.62,"latestTime":"19:15 EST","volume":4058,"amount":59590.85,"timestamp":1770250554851,"change":0.5,"changeRate":0.0342,"amplitude":0.036252},"delay":0,"changeRate":-0.058596265292981335,"floatShares":15692500,"shares":31289969,"eps":-2.10871,"marketStatus":"Not Yet Opened","change":-0.91,"latestTime":"02-04 16:00:00 EST","open":15.53,"high":15.7499,"low":14.54,"amount":12283071.10797,"amplitude":0.077907,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.10871,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770282000000},"marketStatusCode":0,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":15.53,"preHourTrading":{"tag":"盘前","latestPrice":15.53,"preClose":15.53,"latestTime":"09:29 EST","volume":155,"amount":2424.3201249999997,"timestamp":1770215399910,"change":0,"changeRate":0,"amplitude":0.010947},"postHourTrading":{"tag":"盘后","latestPrice":15.12,"preClose":14.62,"latestTime":"19:15 EST","volume":4058,"amount":59590.85,"timestamp":1770250554851,"change":0.5,"changeRate":0.0342,"amplitude":0.036252},"volumeRatio":0.660081,"impliedVol":1.1621,"impliedVolPercentile":0.942},"requestUrl":"/m/hq/s/LENZ/wiki","defaultTab":"wiki","newsList":[{"id":"2609134454","title":"BrainAurora Partners with DODR to Launch Cognitive Digital Therapeutics in Malaysia and Southeast Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2609134454","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609134454?lang=en_us&edition=fundamental","pubTime":"2026-02-05 12:07","pubTimestamp":1770264455,"startTime":"0","endTime":"0","summary":"An update from BrainAurora Medical Technology Limited ( ($HK:6681) ) is now available. BrainAurora Medical Technology Limited has signed a strategi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/brainaurora-partners-with-dodr-to-launch-cognitive-digital-therapeutics-in-malaysia-and-southeast-asia?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/brainaurora-partners-with-dodr-to-launch-cognitive-digital-therapeutics-in-malaysia-and-southeast-asia?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","BK4539"],"gpt_icon":0},{"id":"2609323739","title":"Argenica Therapeutics And 2 Other ASX Penny Stocks Worth Watching","url":"https://stock-news.laohu8.com/highlight/detail?id=2609323739","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609323739?lang=en_us&edition=fundamental","pubTime":"2026-02-05 10:05","pubTimestamp":1770257155,"startTime":"0","endTime":"0","summary":"As the Australian market opens slightly lower today, influenced by global tech sector challenges and cautious investor sentiment, attention turns to opportunities that might be overlooked in more stable times. Penny stocks, often associated with smaller or newer companies, continue to hold potential for those willing to explore beyond established names. These stocks can offer both affordability and growth potential when backed by strong financials; let's examine a few that stand out in the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/argenica-therapeutics-and-2-other-asx-penny-stocks-worth-wat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/argenica-therapeutics-and-2-other-asx-penny-stocks-worth-wat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","SKS.AU","AEF.AU","PPS.AU","BK7143","AGN.AU","BK7503","BK7506","SNS.AU","IGL.AU","BK7077","MXI.AU","BK7050","BK7055","BK7016","DSK.AU","WAF.AU","BK4539","LENZ","BK7104","BK7045","BK4139","SSM.AU","VLS.AU","BK7023","BK7062","BK7128","MTO.AU","BK4007","VRS.AU"],"gpt_icon":0},{"id":"2609034898","title":"PYC Therapeutics Sets Investor Webinar to Detail Capital Raise and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2609034898","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609034898?lang=en_us&edition=fundamental","pubTime":"2026-02-05 09:17","pubTimestamp":1770254245,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited ( ($AU:PYC) ) has issued an update. PYC Therapeutics will host an investor webinar on 24 February 2026, offering sharehold...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-sets-investor-webinar-to-detail-capital-raise-and-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-sets-investor-webinar-to-detail-capital-raise-and-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","PRGS","BK4097","BK4539","LU2065732104.USD","BK4139","BK4007"],"gpt_icon":0},{"id":"2609920223","title":"Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2609920223","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609920223?lang=en_us&edition=fundamental","pubTime":"2026-02-05 02:40","pubTimestamp":1770230428,"startTime":"0","endTime":"0","summary":"Clear Street analyst Kaveri Pohlman believes AbbVie’s (ABBV) plan to bring an extended half-life anti-IL-23 mAb into the clinic this year further v...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clear-street-says-abbvie-move-further-validates-oruka-therapeutics-strategy-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clear-street-says-abbvie-move-further-validates-oruka-therapeutics-strategy-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU1989771016.USD","LU0122379950.USD","IE00B42XCP33.USD","ABBV","LU1162221912.USD","IE00BDGV0183.EUR","LU1585245621.USD","BK4550","LU0943347566.SGD","LU2347655156.SGD","LU1057294990.SGD","LU0708994859.HKD","IE00BJJMRZ35.SGD","IE00BSNM7G36.USD","LU0069063385.USD","LU0310799852.SGD","LU1732799900.SGD","SG9999011175.SGD","IE00BN8TJ469.HKD","LU0256863811.USD","BK4588","LU2237443382.USD","BK4566","LU0320765646.SGD","LU1983299246.USD","BK4533","LU0456855351.SGD","IE00B4R5TH58.HKD","LU0170899867.USD","LU2133065610.SGD","LU2087621335.USD","LU2237443895.HKD","LU0738911758.USD","LU0545039389.USD","LU0861579265.USD","IE0009355771.USD","LENZ","LU0203347892.USD","BK4559","LU0289739699.SGD","LU0689472784.USD","LU0912757837.SGD","LU1839511570.USD","LU0511384066.AUD","IE00BLSP4239.USD","LU1244550577.SGD","LU1989772923.USD","SG9999015978.USD","IE00BVYPNW00.USD"],"gpt_icon":0},{"id":"2609391085","title":"Dogwood Therapeutics: Strengthened Capital Structure, Advancing Pain Pipeline, and Extended IP Support a Buy-Rated Risk-Reward Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2609391085","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609391085?lang=en_us&edition=fundamental","pubTime":"2026-02-05 01:35","pubTimestamp":1770226548,"startTime":"0","endTime":"0","summary":"Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Dogwood Therapeutics. The associated price target remains the same with $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/dogwood-therapeutics-strengthened-capital-structure-advancing-pain-pipeline-and-extended-ip-support-a-buy-rated-risk-reward-profile-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/dogwood-therapeutics-strengthened-capital-structure-advancing-pain-pipeline-and-extended-ip-support-a-buy-rated-risk-reward-profile-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1169590202.USD","BK4136","LU1487256676.USD","LU1481600234.SGD","LU1481599808.USD","BK4007","LU1169589451.USD","BK4539","LENZ","LU2463526074.USD","BK4585","IP","IE00B3T34201.USD","BK4588","BK4139"],"gpt_icon":0},{"id":"2608607853","title":"Cero Therapeutics to present data from Phase 2 trial of CER-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2608607853","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608607853?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:16","pubTimestamp":1770214617,"startTime":"0","endTime":"0","summary":"CERo Therapeutics (CERO) announces a presentation highlighting data to date from the Company’s Phase 1 clinical trial, called CERTAIN-T, of its lea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-to-present-data-from-phase-2-trial-of-cer-1236-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-to-present-data-from-phase-2-trial-of-cer-1236-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4539","BK4007","CERO"],"gpt_icon":0},{"id":"2608367258","title":"Autolus Therapeutics reports inducement grants under Nasdaq listing rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2608367258","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608367258?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:01","pubTimestamp":1770213661,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics (AUTL) announced that the Compensation Committee of the Company’s Board of Directors granted stock option awards to purchase a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/autolus-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/autolus-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUTL","NQmain","BK4007","BK4139","LENZ","BK4539"],"gpt_icon":0},{"id":"2608604943","title":"Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608604943","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608604943?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:57","pubTimestamp":1770213420,"startTime":"0","endTime":"0","summary":"LONDON and GAITHERSBURG, Md., Feb.  04, 2026  (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-ge","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3232081/0/en/Autolus-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2608601813","title":"Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2608601813","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608601813?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:30","pubTimestamp":1770211800,"startTime":"0","endTime":"0","summary":"Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051DOYLESTOWN, Pa., Feb.  04, 2026  (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3232041/0/en/Aprea-Therapeutics-Appoints-Industry-Veteran-Eugene-Kennedy-MD-as-Chief-Medical-Advisor.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","MD","BK4007","LENZ","BK4539","BK4139"],"gpt_icon":0},{"id":"2608364926","title":"Providence Therapeutics Announces World-First Personalized Pediatric mRNA Cancer Vaccine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2608364926","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608364926?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:00","pubTimestamp":1770210000,"startTime":"0","endTime":"0","summary":"Landmark Australian study opens new possibilities for children with aggressive brain tumors and signals opportunity for Canada and USA.CALGARY, AB and BRISBANE, Australia, Feb. 5, 2026 /PRNewswire/ -- Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, is supporting aworld-first clinical trialevaluating personalized mRNA cancer vaccines for children with advanced and treatment-resistant brain tumors.ThePaedNEO-VAX trial, funded by Providence Therapeutics, in combination with the Australian Government and a host of philanthropic donors, is the first multi-site pediatric study to test individualized mRNA vaccines designed specifically for each child's cancer.The trial is co-led by The University of Queensland and the South Australian Health and Medical Research Institute  and will begin in March 2026 across seven pediatric hospitals in Queensland, South Australia, New South Wales, Victoria, and Western Australia. It is sponsored by the Australia & New Zealand C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/providence-therapeutics-announces-world-first-personalized-pediatric-mrna-cancer-vaccine-trial-302678309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","XAO.AU","BK4539","BK7104","BK4007","XKO.AU","XJO.AU","GBM.AU"],"gpt_icon":0},{"id":"2608361891","title":"Avalo Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2608361891","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608361891?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:00","pubTimestamp":1770206400,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Feb.  04, 2026  (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3231886/0/en/Avalo-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","LENZ","BK4007"],"gpt_icon":0},{"id":"2608363110","title":"Viridian Therapeutics Price Target Maintained With a $42.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2608363110","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608363110?lang=en_us&edition=fundamental","pubTime":"2026-02-04 19:32","pubTimestamp":1770204720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VRDN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 04, 2026 06:32 ET (11:32 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2608383363","title":"Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2608383363","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608383363?lang=en_us&edition=fundamental","pubTime":"2026-02-04 19:11","pubTimestamp":1770203495,"startTime":"0","endTime":"0","summary":"Lucid Capital upgraded Tvardi Therapeutics (TVRD) to Buy from Neutral with a $6 price target The firm finds the stock undervalued at current levels...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tvardi-therapeutics-upgraded-to-buy-from-neutral-at-lucid-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tvardi-therapeutics-upgraded-to-buy-from-neutral-at-lucid-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LCID","LENZ"],"gpt_icon":0},{"id":"2608333398","title":"Insider Shake-Up Sends Serina Therapeutics Buzzing","url":"https://stock-news.laohu8.com/highlight/detail?id=2608333398","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608333398?lang=en_us&edition=fundamental","pubTime":"2026-02-04 10:04","pubTimestamp":1770170652,"startTime":"0","endTime":"0","summary":"New insider activity at Serina Therapeutics ( ($SER) ) has taken place on February 3, 2026. Chief Scientific Officer Moreadith Randall unloaded 6,5...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insider-shake-up-sends-serina-therapeutics-buzzing-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insider-shake-up-sends-serina-therapeutics-buzzing-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2608738211","title":"PYC Therapeutics Secures AU$537 Million Through Institutional Placement, Entitlement Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2608738211","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608738211?lang=en_us&edition=fundamental","pubTime":"2026-02-04 08:55","pubTimestamp":1770166525,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  has successfully closed its institutional placement, and the institutional component of its three-for-five pro-rata accelerated non-renounceable entitlement offer, raising AU$537 million in commitments at AU$1.50 per new share, according to a Wednesday filing with the Australian bourse.The placement issued around 85.5 million shares to raise AU$128 million, and the institutional entitlement offer issued about 273 million shares to raise AU$409 million, per the filing.The company has satisfied the condition of its AU$200 million underwriting agreement, ensuring it will raise at least AU$600 million from the placement and entitlement offer, including the retail entitlement offer, the filing said.The retail entitlement offer will be conducted at the same price and ratio as the institutional entitlement offer, allowing eligible retail shareholders to participate, and is expected to close on Feb. 27, the filing added.The funds will be used to extend the company's cash runw","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PYC.AU","BK4539","LENZ","BK4139","BK4007","BK7067"],"gpt_icon":0},{"id":"2608398382","title":"Tryptamine Therapeutics director ups stake with on-market share buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2608398382","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608398382?lang=en_us&edition=fundamental","pubTime":"2026-02-04 08:28","pubTimestamp":1770164881,"startTime":"0","endTime":"0","summary":"An announcement from Tryptamine Therapeutics ( ($AU:ENP) ) is now available. Tryptamine Therapeutics, operating through Entropy Neurodynamics Limit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tryptamine-therapeutics-director-ups-stake-with-on-market-share-buy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tryptamine-therapeutics-director-ups-stake-with-on-market-share-buy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2608614389","title":"CERo Therapeutics Securities Delisted Following Nasdaq Appeal Denial","url":"https://stock-news.laohu8.com/highlight/detail?id=2608614389","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608614389?lang=en_us&edition=fundamental","pubTime":"2026-02-04 06:51","pubTimestamp":1770159086,"startTime":"0","endTime":"0","summary":"CERo Therapeutics Holdings ( ($CERO) ) just unveiled an update. On October 29, 2025, CERo Therapeutics Holdings, Inc., a Delaware-based company, wa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cero-therapeutics-securities-delisted-following-nasdaq-appeal-denial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cero-therapeutics-securities-delisted-following-nasdaq-appeal-denial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NQmain","BK4539","LENZ","BK4007"],"gpt_icon":0},{"id":"2608800329","title":"ADC Therapeutics participates in a conference call with Cantor","url":"https://stock-news.laohu8.com/highlight/detail?id=2608800329","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608800329?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:00","pubTimestamp":1770152427,"startTime":"0","endTime":"0","summary":"Analyst Schmidt holds a conference call with CEO Mallik on February 6 at 1 pm hosted by Cantor.Webcast Link Published first on TheFly – the ultimat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adc-therapeutics-participates-in-a-conference-call-with-cantor-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adc-therapeutics-participates-in-a-conference-call-with-cantor-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4231","ADC","LENZ","BK4139","BK4539","BK4080","BK4007"],"gpt_icon":0},{"id":"2608872720","title":"Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2608872720","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608872720?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:10","pubTimestamp":1770127800,"startTime":"0","endTime":"0","summary":"RICHMOND, Calif., Feb.  03, 2026  (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,19","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/03/3231197/33816/en/Sangamo-Therapeutics-Announces-Pricing-of-25-0-Million-Underwritten-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2608872393","title":"Viridian Therapeutics Is Maintained at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2608872393","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608872393?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:59","pubTimestamp":1770127140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VRDN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 03, 2026 08:59 ET (13:59 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1035773651.USD","IE000M9KFDE8.USD","LU0149725797.USD","LU0640476718.USD","LU2461242641.AUD","LU1267930573.SGD","LU0742534661.SGD","BK4501","LU0267386448.USD","LU0072461881.USD","BK4207","LU0175139822.USD","IE00B7SZLL34.SGD","LU1814569148.SGD","LU1280957306.USD","BK4588","LU0130102774.USD","LU1074936037.SGD","BK4007","LU1894683348.USD","LU0048573561.USD","LU0942090050.USD","LU1201861249.SGD","LU0971096721.USD","IE00B19Z3581.USD","LU0683600562.USD","LU1267930490.SGD","LU0029864427.USD","BK4559","LU0787776722.HKD","LU0310800379.SGD","LU0128525929.USD","LU0162691827.USD","LU1267930227.SGD","LU1506573853.SGD","LU0211327993.USD","LENZ","LU0314106906.USD","LU0128525689.USD","LU0154236417.USD","LU2361044865.SGD","LU0868494617.USD","LU0251131958.USD","LU0208291251.USD","LU0256863811.USD","BK4585","LU0310800965.SGD","LU1668664300.SGD","VRDN","LU1894683264.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.graphitebio.com","stockEarnings":[{"period":"1week","weight":-0.2161},{"period":"1month","weight":-0.1129},{"period":"3month","weight":-0.3632},{"period":"6month","weight":-0.5784},{"period":"1year","weight":-0.4373},{"period":"ytd","weight":-0.0863}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.0769},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.0063}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.046762},{"month":3,"riseRate":0.25,"avgChangeRate":-0.098838},{"month":4,"riseRate":0.5,"avgChangeRate":-0.02248},{"month":5,"riseRate":0.25,"avgChangeRate":-0.134416},{"month":6,"riseRate":0.75,"avgChangeRate":0.05507},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}